Is This California Biopharma Co. In the Right Place at the Right Time?
Research Report
Regenerative Medicine Co. Adds Saudi Arabia Diabetes Initiative
Approval Sought in Japan for New Drug to Lower Cholesterol
Research Report
AI Accelerates Breakthroughs in Cancer Drug Discovery
Intratubal Insemination Device Shown Effective, Safe
Research Report
Developer of Medical Instruments Attracts Research Coverage
Research Report
Two Firms Aim To Create Functional Cure for Type 1 Diabetes
Biotech Initiates Phase III Trial for Heart Disease Drug
Clinical-stage life sciences company Cardiol Therapeutics (CRDL:TSX; CRDL:NASDAQ) is setting up a phase III trial for its pericarditis drug, CardioRx, after pilot study sees success. Read why analysts like this biotech stock.Breakthrough Therapy Shows Promising Long-Term Results for Depression
Cybin Inc. (CYBN:NYSE American; CYBN:NEO) has announced positive results from its 12-month Phase 2 study of CYB003, a proprietary deuterated psilocin program designed for the adjunctive treatment of major depressive disorder (MDD). Find out about the FDA's designation of this treatment and why the Chief Medical Officer sees this news as "highly encouraging."Analyst Says Biotech's Data Supports Advancement Into Phase III
Research Report
Cardiol Therapeutics (CRDL:TSX; CRDL:NASDAQ) recently released updated Phase II data from the MAvERIC trial testing CardiolRx in recurrent pericarditis, according to a Leede Financial Inc. research note. Transformative Moves in Harm Reduction Expanding Market Reach with New Partnerships and Acquisitions
Safe Supply Streaming Co. Ltd (SPLY:CSE; SSPLF:OTCQB; QM4:FSE) recently announced significant developments within its portfolio company, Safety Strips, and a key acquisition. Learn more about how these strategic developments aim to enhance harm reduction efforts and expand market reach.Opportunity Arises for Co. With Cell Pouch
Research Report
This medical device owner could team up with a biotech firm that just prioritized its diabetes program, noted a Leede Financial Inc. report. Rising Revenue and Strategic Pipeline Advances Propel Biotech Growth Trajectory
Vertex Pharmaceuticals Inc. (VRTX:NASDAQ) has reported a robust financial performance for the third quarter of 2024. Read the details on this announcement and some of the primary drivers behind the rise.Regenerative Med Co. Granted Second Tissue License
Research Report
With these expanded capabilities, the biotech may increase revenue generation and continue its clinical trial, noted a Roth MKM report. New Blood Cancer Treatment Shows Continued Response
Research Report
The biotech behind this cell therapy has numerous near-term catalysts related to its pipeline, noted a Wedbush report. Medical Co. Ready for a Transformative F2025
Research Report
The Leede Financial Inc. analyst also noted that while F2024 is a transition year for Profound Medical Corp. (PROF:NASDAQ; PRN:TSX), F2025 is expected to be transformative for U.S. TULSA-PRO adoption. rates. 
Streetwise Key Charts
